Streptococcal and staphylococcal infections result in significant human morbidity and mortality. This study used a transgenic murine model expressing human major histocompatibility complex (MHC) class II and human CD4 in which, without additional toxic sensitization, human-like responses to the bacterial superantigen (SAg) streptococcal pyrogenic exotoxin A (SpeA) could be simulated, as determined by studying multiple biologic effects of the SAgs in vivo. Expression of human leukocyte antigen (HLA)-DQ8 rendered the mice susceptible to SpeA-induced lethal shock that was accompanied by massive cytokine production and marked elevation of serum alanine and aspartate aminotransferase levels. Of importance, this model enabled examination of the efficacy of an engineered non-SAg vaccine candidate against SpeA in the context of HLA. This report is thought to be the first of a lethal shock triggered in mice by bacterial SAgs without prior sensitization and examination of a vaccine against streptococcal SAg in the context of human MHC receptors.
Lethal Shock Induced by Streptococcal Pyrogenic Exotoxin A in Mice Transgenic for Human Leukocyte Antigen-DQ8 and Human CD4 Receptors: Implications for Development of Vaccines and Therapeutics
to be a direct correlation between streptococcal TSS and Speproducing strains [10] . Several distinct forms of superantigens (SAgs) have been defined and are designated SpeA1-4, C, G, H, streptococcal mitogenic exotoxin Z (SME-Z and SME-Z2), and streptococcal SAg [11] [12] [13] [14] [15] . These toxins act as SAgs by virtue of their direct binding to human class II major histocompatibility complex (MHC) and T cell antigen receptors (TCRs), thereby activating a large subset of T cells in the absence of conventional antigen presentation. This multiclonal stimulation of T cells results in massive release of proinflammatory cytokines and other inflammatory mediators thought to be important for inducing TSS [16] [17] [18] [19] [20] [21] .
Most SAgs bind conserved elements in the human MHC class II molecule; however, different SAgs have distinct affinities for different HLA isotypes [12, 22] . Staphylococcal enterotoxins (SEs) display a preferential binding to HLA-DR, whereas SpeA appears to prefer HLA-DQ [23] [24] [25] . In addition, there are differences in the ability of different SAgs to bind to a or b chains of HLA [12, 15, 22] . Although SEB binds exclusively to the a chain, other SAgs (e.g., SEA and SEE) bind to both chains of HLA-DR [26, 27] . Structural and modeling analyses show that SpeA also binds to the a chain of human class II MHC molecule [28, 29] . A potential zinc-binding site has been recognized in SpeA that may mediate the binding of the toxin to MHC class II b chain [28] [29] [30] . In addition, crystallographic studies suggest that SpeA may tetramerize, although the functional relevance of tetramerized complexes is not yet clear [28, 29] .
The pathogenesis of bacterial SAgs cannot be examined easily in mice, because, unlike human and nonhuman primate lymphocyte responses to bacterial SAgs, murine cells respond only to extremely high concentrations of these toxins in vitro [14, 31, 32] . Consequently, mice are significantly less susceptible to the toxic effects of bacterial SAgs, and lethal shock can be induced in mice only when SAgs are administered in combination with lipopolysaccharide or D-galactosamine, an agent that disrupts liver metabolism [17, 21, 31] . Mouse resistance to bacterial SAg toxicity may be due to having significantly lower affinities toward murine MHC class II molecules, which lack a critical lysine residue in the a chain [33] . Therefore, wild-type (WT) mice are not an ideal animal model of the pathogenesis of bacterial SAg or for testing of therapeutic and vaccination approaches against staphylococcal and streptococcal infections.
HLA class II transgenic mice, generated on the background of MHC class II knockout (A b 0 ) mice, are invaluable as models for HLA-associated human diseases [34] [35] [36] [37] . In this study, we analyzed the biologic effects of SpeA produced by S. pyogenes in transgenic mice expressing HLA-DR3 or HLA-DQ8 or in mice expressing HLA-DR2b in association with the murine IEa molecule. Our objectives were to determine whether expression of HLA-DQ8 in these mice restores the toxic response to SAgs, including in vivo expansion of T cells expressing specific variable b (Vb) subsets, proliferative response of T cells in vitro, cytokine surge, and the lethal shock to SAgs. In addition, we wanted to use this humanized model to examine a recombinant attenuated SpeA vaccine and to determine immunogenicity and generation of protective antibodies against WT SpeA.
Materials and Methods
Mice. HLA-DR2, HLA-DR3, and HLA-DQ8/human CD4 ϩ transgenic mice were created by microinjection of DNA fragments into embryos from C57BL/6 mice, as described elsewhere [34, 35] . Injection of HLA-DQa1*0301 and HLA-DQb1*0302 gene fragments created HLA-DQ8 ϩ transgenic mice. The C57BL/6 embryos were inserted into (C57BL/6xDBA/2) F 1 mice and backcrossed to B10.M mice. The HLA-DQ8 molecule was then introduced into murine class II-negative mice by mating the H-2 negative strain (H-2 A b 0/0 ) with HLA-DQ8.B10.M mice. Human CD4 ϩ A b 0 mice were similarly created and subsequently crossed with HLA-DQ8 ) and C57BL/6 (H2 b ) 10-12-weekold mice were obtained from Charles River (National Cancer Institute, Frederick, MD). The mice were maintained under pathogen-free conditions and fed laboratory chow and water ad libitum.
Reagents. Purified recombinant WT SpeA3 was obtained from Toxin Technology and stored at 4ЊC. The endotoxin levels in SpeA were less than detection limits, as determined by the limulus amebocyte lysate QCL-100 endotoxin assay, according to the manufacturer's instruction (BioWhittaker).
Serum cytokine measurements. After mice were injected intraperitoneally (ip) with SpeA (5 mg), serum was collected and pooled from 4 mice per group at various time points. Levels of serum tumor 
Polymerase chain reaction (PCR) and reverse-transcription (RT)-PCR.
Before all experiments, each mouse was evaluated by PCR to determine whether transgene was present in their genome. Mice were bled via the tail (100 mL), and whole blood was used to isolate genomic DNA, according to specifications outlined in the Isoquick nucleic acid extraction kit (Orca Research). Purified DNA was then used for PCR amplification in the presence of 0.8 mM primers, 200 mM each dNTP, and 2.5 U of Amplitaq (Roche). Cycling conditions were programmed in the Stratagene Robocycler for 30 cycles. Each cycle consisted of 30 s at 94ЊC, 1 min at 55ЊC, and 1 min at 72ЊC. The PCR product was run on a 1.8% agarose gel, and bands were detected by ethidium bromide staining.
The following primer sequences were used to detect the presence of the transgenes: DR2, (sense) TCGCCGCTGCACT GTGAAG and (antisense) TCCTGTGGCAGCCTAAGAG; DR3, (sense) CGCTTCGACAGCGAC and (antisense) GACAAATCCACAC-TCCAC; and DQ8, (sense) AGGATTTGGTGTACCAGTTT-AAGGGCAT and (antisense) TGCAAGGTCGTGCGGAGCTC-CAA. We used RT-PCR to evaluate TCR-Vb usage by the splenic T cells of the transgenic mice. RNA was isolated by Trizol extraction (Life Technologies). RNA (1 mg) was reverse transcribed to produce cDNA with the cDNA Cycle Kit (Invitrogen). The RT product was amplified under the following PCR conditions: 50 mL volume containing 5 mL of 10ϫ PCR buffer, 1 mL of 10 mM dNTPs, 1.5 mM MgCl 2 , 1 mM each specific primer, and 1 U of Amplitaq (Perkin Elmer). To analyze the TCR Vb usage, we synthesized different Vb-specific oligonucleotides for use as 5 -sense primers for PCR and a primer for the constant region of the TCR b chain (Cb) for use as a 3 -antisense primer. Each cDNA was also amplified with primers specific for the constant region of TCR-a to assess the efficiency of cDNA synthesis and amplification. The amplified products were separated on 1.8% agarose gels.
We used the following oligonucleotide sequences for Vb regions and as the constant region of TCR-a as standard controls: TCRa, (sense) AAGATCCTCGGTCTCAGGAC and (antisense) GTA GGTG GCGTTGGTCTCTT; TCR-b (antisense, constant), TGCA- Flow cytometry. HLA-DR2, HLA-DR3, HLA-DQ8, and human CD4 expression on peripheral blood mononuclear cells (PBMC) were analyzed as follows: mice were bled from the tail vein, and the PBMC fraction was isolated by centrifugation over a ficoll-histopaque gradient. After a wash with RPMI 1640 medium containing 0.2% bovine serum albumin (BSA), the cells were incubated with one of the following monoclonal antibodies: IVD12 (anti-HLA-DQ), L243 (anti-HLA-DRa), L227 (anti-HLA-DRb), anti-human CD4, or appropriate isotype controls. After an initial 45 min of primary antibody incubation, the cells were washed with RPMI 1640 medium containing 0.2% BSA, incubated for 30 min with a fluorescein isothiocyanate (FITC)-conjugated goat antibody specific for mouse IgG (ICN Biomedicals), and analyzed by Becton Dickinson FACSort cytometer. The expression of murine CD3 receptor on splenic mononuclear cells was determined by flow cytometry, as described above.
Preparation of SpeA mutant vaccine. Engineered SpeA mutant contained the following mutations: N20D, L42A, C87A, C90A, and C98A, with an insertion of AENADHLAYI between residues 89 and 90 that was generated during a test of the effects of random insertions on structure. This mutant protein will be referred to as SpeA915. The mutant protein was purified by ion-exchange chromatography after bacterial lysis. The mutant SpeA915 was 195% pure, as determined by SDS-PAGE. The mutant SpeA protein contained !10 endotoxin U/200 mL, as determined by limulus lysate assay. SpeA915 had no detectable binding to MHC class II on the surface of human B cells and showed no SAg activity, as measured by T cell proliferation.
SpeA915 binding and T cell responses. To measure binding of SpeA915 to MHC class II, the human B lymphoblastoid cell line LG2 was incubated (for 30 min at 37ЊC) with WT or SpeA915 in RPMI 1640 medium containing 0.2% BSA (flow medium). The cells were washed twice with the flow medium and incubated (for 30 min at 4ЊC) with affinity purified anti-SpeA antibody (Toxin Technology). Unbound antibody was removed, bound antibody was detected with FITC-labeled antibody, and the samples were analyzed by flow cytometer (FACSort; Becton Dickinson).
For T cell stimulation, human PBMC were obtained as described elsewhere [38] . In brief, the cells were incubated in RPMI 1640 medium with 5% FBS for 3 days at 37ЊC (in 5% CO 2 at 95% humidity) in the presence of SpeA WT or SpeA915. The cultures were pulsed with 1 mCi Vaccination protocol.
Mice were injected ip with 20 mg of SpeA915 in 100 mL of adjuvant (Ribi Immunochem Research) or with adjuvant alone and boosted at 4 and 8 weeks in the same manner as that described for the primary injection [39, 40] . Mice were challenged 2 weeks after the second boost with 5 mg of WT SpeA and survival was scored over 7 days.
Antibody titers. Serum antibody titers against SpeA were determined by ELISA, as described elsewhere [39, 40] . The mean duplicate absorbance of each treatment group was obtained, and data are presented as the inverse of the highest dilution that produced an absorbance reading twice that of the negative control wells (antigen or serum was omitted from the negative control wells).
Results

Robust T cell proliferation of HLA-DQ8 transgenic mice to
SpeA. Human T cells respond to MHC-bound SAgs with strong proliferative responses. As a first measure of response of HLA-transgenic mice to SpeA, we examined the effects of different transgenes on SpeA-induced T cell proliferation and compared them with human responses. Human PBMC and splenocytes from different transgenic and BALB/c mice were stimulated in vitro for 72 h with increasing concentrations of SpeA, and T cell proliferation was measured.
As shown in figure 1A , the response of T cells derived from HLA-DQ8 mice was significantly higher than the responses from other transgenic or BALB/c mice and were comparable to the human T cell responses. SpeA at 1 ng/mL induced a level of proliferation in HLA-DQ8 splenocytes comparable to levels induced by 1 mg/mL toxin in BALB/c or HLA-DR3 mice, which suggested a 1000-fold higher sensitivity in terms of proliferative dose response (figure 1). The decreased proliferation of HLA-DQ8 cells at 1 mg/mL toxin (figure 1A) was due to the saturation of culture and consequent cell death, as assessed by trypan blue exclusion (data not shown). Figure 1B shows the same data as those in figure 1A , except for HLA-DQ8 and human T cell responses in an expanded scale. HLA-DR3 splenocytes had a stronger response at 10-100 ng/mL of SpeA than did the splenocytes from BALB/c and HLA-DR2b/IEa mice that lack the HLA-DRa chain (figure 1B). Thus, expression of both a and b chain from human MHC resulted in greatly enhanced responses to SpeA.
HLA-DQ8 transgenic mice are highly susceptible to SpeAinduced lethal shock. Mice are less sensitive to SAg-induced septic shock than primates. SAg-induced lethal shock in mice occurs when the biologic activity of the SAgs is potentiated by agents such as D-galactosamine or lipopolysaccharide [17, 21] . This lower sensitivity is most likely due to lower affinity of SAgs for mouse MHC class II receptors and consequently reduced T cell responses.
To see whether the high efficiency of HLA-DQ8 responses to SpeA in vitro translates to significant increase in biologic effects in vivo, we monitored survival of WT and various transgenic mice after administration of different doses of SpeA. As shown in table 1, SpeA at 5 and 20 mg was lethal to 100% of mice transgenic for HLA-DQ8, lethality occurred within 48-72 h of injection, and 3 mg of the toxin was sufficient to induce lethal shock in 80% of the HLA-DQ8 mice. Although the lower dose of SpeA was not lethal, the mice showed visible distress. In contrast to HLA-DQ8 mice, none of the HLA-DR3, DR2b/ IEa, BALB/c, or C57BL/6 mice died when challenged at doses as high as 20 mg and none showed any signs of distress. Those surviving the challenge at 72 h were monitored for у3 weeks. There was no delayed lethality in any of these mice. These data clearly show that the expression of HLA-DQ8 and human CD4 renders mice susceptible to SpeA-induced lethal shock without prior sensitization.
In vivo cytokine responses of HLA transgenic mice to SpeA. Because we found that SpeA induced lethal shock in HLA-DQ8 human CD4 transgenic mice and because proinflammatory cytokine induction is critical for SAg-induced lethal shock, we measured in vivo cytokine responses to SpeA by mice carrying different HLA alleles. Our initial studies indicated that SpeA induced comparable cytokine responses in C57BL/6 and BALB/c mice and in mice transgenic for HLA-DR2b that express HLA-DR2b in association with IEa (lacking DRa) (data not shown). Therefore, we used HLA-DR2b/IEa mice as controls, because these mice have the same background as the other HLA transgenic mice used in this study.
Mice received 5 mg of SpeA (ip), were bled 4 h after injection, and serum cytokines were measured. As shown in figure 2, SpeA induced very low levels of IL-6 and IFN-g in HLA-DR2b/IEa mice, and TNF-a was undetectable at this time point. At later time points, up to 40-60 pg/mL of TNF-a was detected in the serum of treated DR2b/IEa mice (data not shown). HLA-DQ8 transgenic mice had the strongest response; HLA-DR3 mice responded weakly, yet their response was much higher than that of HLA-DR2b/IEa mice (figure 2). These data are consistent with the reported preferred binding of SpeA to HLA-DQ [24, 25] .
SpeA-mediated induction of liver enzymes. Because we observed a massive increase in serum cytokines in HLA-DQ8 transgenic mice and because overproduction of cytokines has been associated with liver damage, we next explored the possible contribution of elevated cytokine levels to the pathogenesis of SpeA [41] [42] [43] . HLA-DQ8 and HLA-DR2b/IEa transgenic mice were injected with 20 mg of SpeA, and, as a marker of hepatotoxicity, we measured liver enzyme ALT and AST levels at different time points after injection (figure 3). Measurable levels of both AST and ALT were observed 8 h after SpeA injection in HLA-DQ8 mice. Peak responses to SpeA were observed 20 h after injection. At this time point, all HLA-DQ8 mice were visibly stressed. By 24 h, most of the HLA-DQ8 mice succumbed to the SpeA lethal shock, and, at 48 h, all mice were dead. In stark contrast, no elevation in serum AST and ALT levels was observed in HLA-DR2b/IEa transgenic mice injected with 20 mg of SpeA. These data suggest that the inflammatory cytokine induced by SpeA may cause liver damage and provide an additional insight into the mechanism of SpeA toxicity. These 2 liver enzymes may also provide easy monitoring as markers for SAg-producing streptococcal infections and possibly other SAg-induced septic shock. ) and HLAn p 5 DR2b/IEa (filled symbols; ) mice were injected with 20 mg of n p 5 SpeA, and serum from individual mice were obtained at 0, 1, 6, 20, and 60 h. The liver enzymes aspartate aminotransferase (circles) and alanine aminotransferase (squares) were measured. Data are mean ‫ע‬ of 3 mice in each group. Similar results were obtained in 2 inde-SD pendent experiments. All HLA-DQ8 mice injected with SpeA died before the 60-h time point.
In vivo effects of SpeA on specific TCR Vb-expressing T cells.
SAgs show preferential affinity for distinct subsets of Vb-expressing T cells [12] . By use of RT-PCR, we analyzed the effect of SpeA on the relative abundance of splenic T cells expressing different Vb chains in HLA-DQ8 transgenic mice. Mice were injected with PBS or a sublethal dose (1 mg) of SpeA, and splenocytes were prepared after 40 h and analyzed by PCR for TCR Vb expression. As shown in figure 4A , PCR analysis revealed an increase in the relative expression of mRNAs for TCR Vb8, 8.2, 8.3, and 14, whereas the level of Vb6 cells was reduced to undetectable levels. The expression of TCR Vb4 was unaffected by SpeA. These data demonstrate that Vb restricted modulation of T cells could be reproduced in vivo in HLA-DQ8 transgenic mice.
Another biologic factor that has been linked to the diseases induced by SpeA is a massive increase in the number of activated T cells. To confirm this in this model, we examined the in vivo proliferative response of T cells from HLA-DQ8 transgenic mice to SpeA. The transgenic mice were injected with 1 mg of SpeA (a sublethal dose; see table 1) or PBS as control, and the percentage of CD3 ϩ cells in the spleen was determined 40 h after injection. In 3 independent experiments, flow cytometry showed CD3 ϩ cells in the spleens of 19.09% ‫ע‬ 4.47% HLA-DQ8 mice injected with PBS ( figure 4B ). Injecting SpeA into HLA-DQ8 transgenic mice resulted in marked splenomegaly, and the CD3 ϩ cell population more than doubled to (figure 4B).
43.5% ‫ע‬ 4.34%
HLA-DQ8 transgenic mice as a model to examine vaccines against bacterial SAgs. The above data confirmed that the toxicity of SpeA in HLA-DQ8 transgenic mice was mainly exerted through a mechanism dependent on the expression of human MHC class II molecules and was linked to stimulated cytokine release and T cell proliferation. Therefore, this model provides an opportunity to examine vaccines against streptococcus-producing SAg in the context of human MHC class II molecules.
Previously, we reported that key mutations within receptorbinding regions of bacterial SAg SEA and SEB substantially attenuated superantigenic properties of these toxins [39, 44] . Vaccination with these nonsuperantigenic form of toxins protected against challenge with the WT toxin [39, 44] . By using similar strategies, we sought to produce a vaccine candidate for SpeA and then to test the vaccine in the context of human MHC class II receptor. To do this, the TCR and MHC class II binding sites of WT SpeA were extensively mutated with substitutions in 5 key amino acid residues (see Materials and Methods). The mutant SpeA (referred to as SpeA915) had substantial secondary structure at 37ЊC but was greatly destabilized relative to WT SpeA, as assessed by circular dichroism and differential scanning calorimetry (data not shown). The binding of SpeA915 to HLA class II molecules on the surface of LG2 cells was substantially reduced, compared with WT SpeA (figure 5A ). These data suggest that the mutations successfully ablated the ability of SpeA915 to bind to cell surface HLA class ϩ control mice and HLA-DQ8 mice injected with SpeA were used to isolate mRNA and were analyzed by reverse-transcription polymerase chain reaction (PCR). TCR a constant region was amplified with each Vb region in the same reaction as the reference. PCR products were resolved on agarose gels, and band density was determined by densitometry. Data are shown as the ratio of the density of each Vbspecific band divided by the reference band in the same reaction. B, Expansion of CD3 cells after SpeA challenge. HLA-DQ ϩ mice were injected with PBS (control) or 2 mg of SpeA. Splenocytes were prepared after 40 h, and the percentage of total splenocytes expressing CD3 was determined by flow cytometry. Data are of 3 independent mean ‫ע‬ SD experiments, each with 2 mice. II molecules. Likewise, substantial T cell proliferation was induced by WT SpeA, whereas the mutant SpeA915 caused little to no stimulation of human T cells ( figure 5B ). These data clearly show that both binding to MHC class II and T cell superantigenic activities of SpeA was substantially reduced and that SpeA915 no longer possessed WT SAg activity.
Given the attenuation of receptor binding and superantigenicity observed with mutated SpeA, we next injected HLA-DQ8 transgenic mice with SpeA915 and determined biologic toxicity in mice. As expected, there was a substantial decrease in toxicity (10/10 mice survived). To investigate immunogenicity of the SpeA915, HLA-DQ8/human CD4 transgenic mice were vaccinated with 3 doses, 2 weeks apart, of SpeA915 in adjuvant. The control group was injected in the same manner with adjuvant only. On the day of each vaccination, serum titers against WT SpeA were measured by conventional ELISA (table 2). The transgenic mice quickly elicited anti-SpeA antibodies, and, after the second vaccination, their serum anti-SpeA titers reached 1:1000. Two weeks after the last boost, mice injected with SpeA915 elicited antibody titers у1:10,000 (table 2) . Mice vaccinated with adjuvant only developed no antibody against SpeA.
To see whether the immune responses against SpeA915 translated to protection in vivo, 2 weeks after the third vaccination, the transgenic mice were challenged with 5 mg of WT SpeA, and survival was scored ( figure 6 ). In the first 24 h, WT SpeA induced lethal shock in 50% of the transgenic mice vaccinated with adjuvant only. By 72 h, all mice vaccinated with adjuvant only had died. All the transgenic mice vaccinated with SpeA915 survived the challenge. These data suggest that the HLA-DQ8/human CD4 transgenic mouse may be an ideal small animal model to test efficacy of vaccines and potential therapeutics against bacterial SAgs in the context of human MHC molecules.
Discussion
In an attempt to generate an animal model for human immunologic disorders, autoimmune diseases in particular, transgenic mice lacking the endogenous class II MHC (A b 0 ) have been generated that express different class II HLA alleles along NOTE. Data are reciprocal of serum dilution resulting in optical density reading twice that of negative controls (wells containing either no SpeA or no primary antibody). Mice were vaccinated with SpeA915 or adjuvant alone 3 times, on days 0, 28, and 56. Serum titers were determined on day of vaccination and 14 days after the last vaccine administration. with human CD4 molecule [34, 37, 45] . These "humanized" mice are of great value in the study of human immune responses. CD4 T cells generated in these mice recognize the same epitopes as human T cells, and a T cell repertoire similar to that of humans was selected in the thymus of these mice [34] [35] [36] [37] 45] . Because the interaction of SAgs with class II HLA is critical for their toxic actions, we reasoned that such humanized mice should be a useful model for mimicking the human responses to SAgs and could be used as a model for evaluating potential vaccines and therapeutics against bacterial SAgs.
Our data demonstrate that typical responses to streptococcal exotoxin SpeA can be triggered in HLA class II transgenic mice, including rapid cytokine release, proliferation of T cells in vivo and in vitro, and selection of specific Vb-expressing T cells. Less than 2 days after injection of SpeA, the percentage of splenic T cells was increased by 2-3-fold in HLA-DQ8 transgenic mice.
Of note, total T cells in the spleens of HLA transgenic mice was reduced to ∼15%-20% of total splenocytes, compared with WT mice. This may have been due to a more restricted thymic selection as a result of lack of murine MHC class II and murine CD4 and restriction of all CD4
ϩ T cells to a single class II MHC molecule. The measured responses were much higher in the mice expressing both chains of human HLA class II than in BALB/c mice or HLA-DR2b/IEa control mice. The highest activity, with respect to the proliferation of splenic T cells in particular, was observed in HLA-DQ8 transgenic mice. The proliferative response of splenocytes from HLA-DQ8 transgenic mice to SpeA was significantly higher than that of HLA-DR3 transgenics. This finding is consistent with the reported preferred binding of SpeA to HLA-DQ [24, 28, 46] .
Imanishi et al. [46] showed that, despite undetectable direct binding, SpeA can induce T cell proliferation when L cells transfected with HLA-DR are used as antigen-presenting cells. Our data show that HLA-DR3 transgenic mice developed a measurable response to SpeA, but the magnitude of the reaction was far less than that of the HLA-DQ8 transgenic mice. The discrepancy between the 2 studies may be explained by the possibility that, in the studies performed by Imanishi et al. [46] , overexpression of HLA-DR on L cells may have partially overcome the requirement for a high-affinity binding of the toxin. We cannot exclude the possibility that a distinct T cell repertoire with lower susceptibility to SpeA might have been selected in the thymus of HLA-DR3 transgenic mice. Studies are underway to examine this possibility. Taken together, our findings suggest that in vivo HLA-DQ8 molecules play a major role in mediating the toxicity of SpeA.
High levels of cytokines induce elevation of liver enzymes and cause hepatocellular injury [41] [42] [43] . Recently, Sriskandan et al. [47] found that inoculation of SpeA-producing streptococci induced histopathologic changes in the liver of HLA transgenic mice. In this study, we observed elevation in both ALT and AST levels shortly after administration of SpeA to HLA-DQ8 transgenic mice. At 20 h after SpeA challenge, serum levels of these enzymes increased 300%-350%, compared with baseline levels. We found no increase in ALT or AST levels in HLA-DR2b/IEa transgenic mice injected with SpeA. This suggests to us that the mechanism of toxicity is clearly dependent on expression of human MHC class II heterodimer and that these enzymes could be used as biomarkers of SpeA-induced toxicity. Induction of liver damage by bacterial SAgs was reported elsewhere [48] [49] [50] . However, in those studies, mice were treated mice with D-galactosamine, an agent known to induce liver damage. Therefore, it is very difficult to interpret data obtained from D-galactosamine-intoxicated mice.
Crystallography data for mouse TCR in complex with SEB, SEC2, and SEC3 indicate amino acid residues within complementarity-determining region (CDR) 2 of TCR Vb to be mainly involved in binding to the SAgs, but interactions with CDR1 and CDR4 are detected [51, 52] . Indirect evidence suggests that perhaps SpeA also interacts with the same CDR regions of the TCR b chain and induces the clonal expansion of T cells expressing specific Vb chains [12, 24] . In humans, SpeA stimulates Vb 2-, Vb 12-, Vb 14-, and Vb 15-expressing T cells [53] . An expansion of Vb 8-expressing human T cells by SpeA has also been reported elsewhere [54] . In the absence of human MHC class II molecules, SpeA only activates T cells expressing Vb 8.2 in mice [46, 55] . HLA-DQ8 transgenic mice, challenged with SpeA increased the percentage of TCR Vb 8.2-expressing cells in vivo, consistent with in vitro data in nontransgenic mice reported by Imanishi et al. [46] . However, we also observed expansion of T cells expressing Vb 3, Vb 7, Vb 8.3, and, to a lesser degree, Vb 14 and Vb 17 ( figure 5A; data not shown) . Therefore, in the presence of human MHC, more efficient presentation of SpeA may occur, resulting in higher T cell responses. This suggests that the nature of the MHC molecule might have an instructive effect on the choice of TCR by the superantigen.
Yeung et al. [56] demonstrated that expression of HLA-DQ6 transgene renders mice more sensitive to SEB. Despite significantly higher sensitivity, these DQ6 ϩ mice still need sensitization by D-galactosamine for lethal shock [56] . Whether this is due to the nature of DQ6 versus DQ8 molecules or whether a full response to SEB requires the presence of HLA-DR remains to be elucidated. In addition, while we were preparing this manuscript, Sriskandan et al. [47] published their findings on the effects of SpeA potentiated with D-galactosamine on HLA-DQ8 transgenic mice. Enhanced sensitivity of HLA-DQ8 transgenic mice was apparent only when biologic activities of SpeA were enhanced with D-galactosamine. This apparent lack of biologic response to SpeA may have occurred because the transgenic mice they used was not knocked out for mouse MHC class II, and residual mouse class II or lower expression of the transgene may have contributed to inefficient response.
SpeA toxoids have been produced by multiple amino acid substitutions, including those at positions N20, L42, and C98, the same residues altered in our mutant construct [57, 58] . In a rabbit miniosmotic pump system, this mutant protected against challenge with WT SpeA. However, these vaccines were tested in the context of rabbit MHC class II molecules and not the proper SAg receptor human MHC class II molecule. Furthermore, peptides including sequences highly conserved among SAgs have been identified that provide extensive crossprotection against challenge with a number of SAgs in rabbit and sensitized mouse models [59, 60] . The wide range of protection against SAgs provided by these consensus-sequence peptides is not in apparent agreement with our previous findings and with the findings by Roggiani et al. [58] and others [40] that intact protein toxoids of TSS toxin-1 and SpeA are not fully cross-protective [40, 58] . The prospect that a conserved region of superantigens contains a cryptic epitope capable of providing protection against a significant subset of the many naturally occurring SAgs increases hope for a generally useful vaccine, although whether such peptides can be adequately presented by human MHC molecules is untested.
Consensus peptides have therapeutic effects [59, 60] and block the toxicity of superantigens. The mechanism of this effect is unknown, although Visvanathan et al. [60] provide some evidence for direct peptide binding to MHC, which possibly block the superantigen binding site. Various reports suggest that bacterial SAg interactions with immune cells favor release of T helper (Th) 1 type cytokines, which drive the inflammatory cascade and possibly lethal shock [2, 12] . More recently, Arad et al. [61] showed that synthetic peptides specifically block Th1 type cytokine production. Thus, these peptides may tip the balance in favor of Th2 type cytokines. The mouse model with a humanized MHC that we describe would appear to be a superior system for testing of the therapeutic effects of such peptides and compounds modeled on it, because it actually includes the appropriate target receptors.
Our findings suggest that HLA-DQ8/human CD4 transgenic mice may be a useful model for evaluating vaccine efficacy and for screening potential drugs against Spe and possibly other bacterial SAgs. We demonstrated lethal shock induced in mice by SpeA without prior sensitization. This is particularly important, because evaluation of protective effects of vaccines or therapeutics cannot be based solely on laboratory parameters such as cytokine release, antibody titers, or effector cell appearance. We are currently analyzing the efficacy of multiple SAg vaccine and therapeutic candidates in this model. More studies are needed to examine the response to other bacterial SAgs in mice transgenic for single or multiple HLA class II alleles. In addition, we envisage that this model will be useful for the study of autoimmune diseases possibly related to SAg exposure.
